Država: Sjedinjene Američke Države
Jezik: engleski
Izvor: NLM (National Library of Medicine)
Clobetasol Propionate (UNII: 779619577M) (Clobetasol - UNII:ADN79D536H)
Taro Pharmaceuticals U.S.A., Inc.
TOPICAL
PRESCRIPTION DRUG
Clobetasol Propionate Topical Spray, 0.05% is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older. The total dosage should not exceed 50 g (59 mL or 2 fl. oz.) per week. Do not use more than 26 sprays per application or 52 sprays per day. Treatment should be limited to 4 consecutive weeks. Patients should be instructed to use Clobetasol Propionate Topical Spray, 0.05% for the minimum amount of time necessary to achieve the desired results [see Dosage and Administration (2) ]. Use in patients under 18 years of age is not recommended because safety has not been established and because numerically high rates of HPA axis suppression were seen with other clobetasol propionate topical formulations. Clobetasol Propionate Topical Spray, 0.05% should not be used on the face, axillae, or groin. Clobetasol Propionate Topical Spray, 0.05% should not be used if there is atr
Clobetasol Propionate Topical Spray, 0.05% is a clear, colorless liquid, supplied in a white HDPE bottle with a white polypropylene cap and white LDPE liner in the following sizes: 2 fl oz/59 mL NDC 51672-1371-4 4.25 fl oz/125 mL NDC 51672-1371-8 Storage: Keep tightly closed. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze, refrigerate or store above 30°C. Spray is flammable; avoid heat, flame or smoking when using this product.
Abbreviated New Drug Application
CLOBETASOL PROPIONATE- CLOBETASOL PROPIONATE SPRAY TARO PHARMACEUTICALS U.S.A., INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE CLOBETASOL PROPIONATE TOPICAL SPRAY, 0.05% SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CLOBETASOL PROPIONATE TOPICAL SPRAY, 0.05%. CLOBETASOL PROPIONATE SPRAY, 0.05%, FOR TOPICAL USE INITIAL U.S. APPROVAL: 1985 INDICATIONS AND USAGE Clobetasol Propionate Topical Spray, 0.05% is a corticosteroid indicated for the topical treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older. (1.1) Limitations of Use: Do not use on the face, axillae or groin. (1.2) Do not use if atrophy is present at the treatment site.(1.2) Do not use for rosacea or perioral dermatitis. (1.2) DOSAGE AND ADMINISTRATION Not for oral, ophthalmic, or intravaginal use. (1.2) Clobetasol Propionate Topical Spray, 0.05% should be sprayed directly onto the affected skin areas twice daily and rubbed in gently. (2) The total dosage should not exceed 50 g (59 mL or 2 fluid ounces) per week. Do not use more than 26 sprays per application or 52 sprays per day. (2) Clobetasol Propionate Topical Spray, 0.05% contains a super-high potent topical corticosteroid; therefore treatment should be limited to 4 weeks. Treatment beyond 2 weeks should be limited to localized lesions of moderate to severe plaque psoriasis that have not sufficiently improved after the initial 2 weeks of treatment with Clobetasol Propionate Topical Spray, 0.05%. (2) DOSAGE FORMS AND STRENGTHS Spray, 0.05% w/w (3) CONTRAINDICATIONS None. (4) WARNINGS AND PRECAUTIONS Clobetasol propionate is a highly potent topical corticosteroid that has been shown to suppress the HPA axis at the lowest doses tested. (5.1) Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. (5.1) Systemic absorption may require periodic evaluation Pročitajte cijeli dokument